Literature DB >> 7504360

Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines.

M A Rogawski1.   

Abstract

NMDA and non-NMDA (AMPA/kainate) antagonists have potential in the treatment of a diverse group of neurological disorders associated with excessive activation of excitatory amino acid receptors. Here Michael Rogawski reviews recent progress in the development of therapeutically useful NMDA receptor channel blockers and a new class of selective AMPA/kainate receptor antagonists, the 2,3-benzodiazepines. Research on these novel noncompetitive excitatory amino acid antagonists has opened promising new avenues for the development of drugs to treat epilepsy, ischaemia, neurodegeneration and Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7504360     DOI： 10.1016/0165-6147(93)90005-5

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  49 in total

1.  Domain interactions regulating ampa receptor desensitization.

Authors:  K M Partin
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

2.  Neuroprotective effect of GMP in hippocampal slices submitted to an in vitro model of ischemia.

Authors:  Ivaldo J L Oliveira; Simone Molz; Diogo O Souza; Carla I Tasca
Journal:  Cell Mol Neurobiol       Date:  2002-06       Impact factor: 5.046

3.  Comparison of the anticonvulsive activities of organic mono- and dications with their abilities to inhibit NMDA and AMPA glutamate receptors.

Authors:  N Ya Lukomskaya; N I Rukoyatkina; L V Gorbunova; V E Gmiro; K V Bol'shakov; L G Magazanik
Journal:  Neurosci Behav Physiol       Date:  2004-02

4.  Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses.

Authors:  Peng Xia; Huei-sheng Vincent Chen; Dongxian Zhang; Stuart A Lipton
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

5.  Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats.

Authors:  M Bubser; T Tzschentke; W Hauber
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 6.  Diverse mechanisms of antiepileptic drugs in the development pipeline.

Authors:  Michael A Rogawski
Journal:  Epilepsy Res       Date:  2006-04-18       Impact factor: 3.045

7.  Mechanisms of the blockade of glutamate channel receptors: significance for structural and physiological investigations.

Authors:  L G Magazanik; D B Tikhonov; T B Tikhonova; N Ya Lukomskaya
Journal:  Neurosci Behav Physiol       Date:  2007-03

8.  7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys.

Authors:  D M Thompson; A Guidotti; M DiBella; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

9.  Antiparkinsonian effect of flupirtine in monoamine-depleted rats.

Authors:  M Schwarz; M Nolden-Koch; J Purr; G Pergande; F Block
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

10.  Behavioral studies on FR115427, a novel selective N-methyl-D-aspartate antagonist.

Authors:  H Nakanishi; K Katsuta; Y Ueda; H Takasugi; A Kuno; M Ohkubo; K Ogita; Y Yoneda; K Shirakawa; K Yoshida
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.